Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
OptiNose, Inc. OPTN
$1.96
-$0.02 (-1.26%)
На 18:00, 12 мая 2023
+129.59%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
216911400.00000000
-
week52high
4.30
-
week52low
1.55
-
Revenue
76276000
-
P/E TTM
-2
-
Beta
-0.22041500
-
EPS
-0.89000000
-
Last Dividend
0.00000000
-
Next Earnings Date
11 мая 2023 г. в 12:00
Описание компании
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It is also developing OPN-019 that combines liquid EDS device with an antiseptic. The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail; and Inexia Limited to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2000 and is headquartered in Yardley, Pennsylvania.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Cantor Fitzgerald | Overweight | 05 мар 2020 г. | |
| Cowen & Co. | Outperform | 18 дек 2019 г. | |
| BMO Capital | Outperform | Outperform | 13 авг 2019 г. |
| Cantor Fitzgerald | Overweight | Overweight | 14 ноя 2018 г. |
| BMO Capital | Outperform | Outperform | 15 авг 2018 г. |
| BMO Capital | Outperform | Outperform | 14 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Mahmoud Ramy A | A | 549202 | 549202 | 30 янв 2023 г. |
| Mahmoud Ramy A | A | 522055 | 336135 | 30 янв 2023 г. |
| Marino Michael F III | D | 180353 | 5241 | 13 янв 2023 г. |
| Miller Peter K | D | 853384 | 29664 | 13 янв 2023 г. |
| Mahmoud Ramy A | D | 185920 | 8148 | 13 янв 2023 г. |
| Janis Michele | D | 48927 | 1015 | 16 дек 2022 г. |
| Marino Michael F III | D | 185594 | 2751 | 16 дек 2022 г. |
| Clavelli Victor M | D | 199955 | 3208 | 16 дек 2022 г. |
| Miller Peter K | D | 883048 | 15253 | 16 дек 2022 г. |
| Janis Michele | A | 49942 | 1333 | 15 дек 2022 г. |
Новостная лента
OptiNose Inc. (OPTN) Q1 2023 Earnings Call Transcript
Seeking Alpha
11 мая 2023 г. в 17:57
OptiNose Inc. (NASDAQ:OPTN ) Q1 2023 Results Conference Call May 11, 2023 8:00 AM ET Company Participants Jonathan Neely - VP of IR and Business Operations Ramy Mahmoud - CEO and Director Conference Call Participants Brandon Folkes - Cantor Fitzgerald Operator Good day, and thank you for standing by. Welcome to the OptiNose's First Quarter 2023 Earnings Conference Call.
OptiNose (OPTN) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
11 мая 2023 г. в 10:40
OptiNose (OPTN) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.31 per share a year ago.
Optinose Announces Reporting Date for First Quarter 2023 Financial Results
GlobeNewsWire
01 мая 2023 г. в 16:30
Conference Call and Webcast to be held May 11, 2023, at 8:00 a.m. Eastern Time Conference Call and Webcast to be held May 11, 2023, at 8:00 a.m. Eastern Time
Optinose to Present at the Needham Virtual Healthcare Conference
GlobeNewsWire
12 апр 2023 г. в 16:00
YARDLEY, Pa., April 12, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the Needham Virtual Healthcare Conference on April 17, 2023 at 3:45 p.m. ET.
OptiNose (OPTN) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
07 мар 2023 г. в 09:47
OptiNose (OPTN) delivered earnings and revenue surprises of -6.25% and 3.12%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?